AEON Biopharma, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

AEON$0.18-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data) (Unaudited)


	Three Months Ended
· · March 31,
· · 2025 · 2024
Operating expenses: · · · ·
Selling, general and administrative		$3,125	$4,649
Research and development		825	5,732
Change in fair value of contingent consideration		(3,488)	63,769
Total operating costs and expenses		462	74,150
Loss from operations		(462)	(74,150)
Other income (loss):
Change in fair value of convertible notes		(1,631)	(87)
Change in fair value of warrants		86,729	(20,903)
Loss on issuance of warrants		(75,644)	—
Loss on embedded forward purchase agreements and derivative liabilities, net		—	(22,917)
Other income, net		103	39
Total other income (loss), net		9,557	(43,868)
Income (loss) before taxes		9,095	(118,018)
Income taxes		—	—
Net income (loss)		$9,095	$(118,018)
Basic and diluted net income (loss) per share		$2.28	$(227.87)
Weighted average shares of common stock outstanding used to compute basic and diluted net income (loss) per share		3,984,876	517,915

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.